Source: Annual Congress 2001 - Presentation and imaging of TB
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. C. Loh, S. Z. Samah, A. Zainuddin, G. L. S. Wong, W. H. Gan, W. S. Yusuf, P. Vijayasingham (Seremban, Negeri Sembilan, Malaysia). The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence. Eur Respir J 2001; 16: Suppl. 31, 3119

Member's Comments

No comment yet.

Related content which might interest you: The comparative analysis of treatment effectiveness in children and adolescents with MDR TB with anti-TB drugs of the first and second lines Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017 Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB Source: Eur Respir J 2016; 47:1581-1584 Year: 2016 The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47:1758-1766 Year: 2016 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 A Cuban successful history on antituberculosis treatment and drug resistance surveillance Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 First-line anti-TB drug resistance pattern and its trend in the national TB referral center in Iran Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008 The effectiveness of the treatment of patients with TB in the condition adapted DOTS-strategy in Ukraine Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 First line anti-tuberculous drug resistance prevalence and its pattern among HIV infected patients in the national referral TB center, Iran Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Using results of drug sensitivity of infection source in initial chemotherapy choice in TB children and teenagers Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Appreciation efficiency of standard and alternative antituberculosis preventive therapy in children from different tuberculosis infection sources Source: Eur Respir J 2006; 28: Suppl. 50, 28s Year: 2006 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010